Skip to content

News Category: Health & Medical

Ascensia Diabetes Care Presents News Research Showing that People Uing the Contour(R) Blood Glucose Monitoring System and App Experience Few Out-Of-Target Blood Glucose Levels

By asianet

Ascensia Diabetes Care, a global diabetes care company, maker of CONTOUR(R) blood glucose monitoring (BGM) system portfolio and distributor of the Eversense(R) continuous glucose monitoring (CGM) system, announces a new study demonstrating that people who use the connected CONTOUR(R) BGM systems (BGMS) and CONTOUR(R)DIABETES App (CDA) for at least six months can see a reduced … Continued

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

By asianet

Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ … Continued

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

By asianet

Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio’s protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan. Logo – https://mma.prnewswire.com/media/1803052/Healion_Bio_Logo.jpg Dr. Sina … Continued

Varian Partners with Icon Group to Advance Patient-Centric Solutions

By asianet

– Bringing clinical insights into early product development Varian, a Siemens Healthineers company (Varian), today announced a five-year research and professional services agreement with Icon Group (Icon). Through this agreement, Icon will participate in clinical and technical research programs, product evaluation projects, and clinical consultations with Varian to offer Icon’s clinical expertise and industry perspectives … Continued

HealthBeats Raises US$3m Seed Funding Led By Heritas Capital And SEEDS Capital To Expand Remote Vitals Monitoring In Australia And Singapore

By asianet

HealthBeats(TM), a Singapore-based healthtech start-up with end-to-end remote vitals monitoring solution, today announced the close of a US$3m Seed round led by healthcare investor Heritas Capital together with SEEDS Capital, the investment arm of government agency Enterprise Singapore. The HealthBeats(TM) Remote Vitals Monitoring platform provides healthcare providers and patients with a simple-to-use and simple-to-deploy solution … Continued

Zimmer Biomet’s mymobility is recognized as “The Care Management Initiative of the Year” by the 2022 Healthcare Asia Medtech Awards

By asianet

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the company’s mymobility(R) digital care management platform won “The Care Management Initiative of the Year” award at this year’s Healthcare Asia Medtech Awards. mymobility(R) is a digital care management platform that uses iPhone(R) and Apple Watch(R) or Android devices … Continued

Glooko Appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors

By asianet

Glooko, Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the appointment of Alfonso “Chito” Zulueta to its Board of Directors. Logo – https://mma.prnewswire.com/media/1043398/Glooko_Logo.jpg Respected as a leader with a strong track record of success in the pharmaceutical industry and deep experience on corporate … Continued

FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

By asianet

Direct Biologics ( https://c212.net/c/link/?t=0&l=en&o=3515622-1&h=961943011&u=https%3A%2F%2Fwww.directbiologics.com%2F&a=Direct+Biologics ), a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first … Continued

Seegene unveils world’s first commercialized ‘3 Ct’ PCR assay

By asianet

-Provides Ct value of three targets in one channel; ‘3 Ct’ PCR assay to launch in H1 -“Dream MDx technology” developed based on Seegene’s 20-year expertise; combines 19 different patented technologies, including DPO(TM), TOCE(TM), MuDT(TM)-‘3 Ct’ to lay foundation for automated syndromic testing and make MDx more accessible Seegene Inc. (KQ096530), South Korea’s leading molecular … Continued